GSK3B, glycogen synthase kinase 3 beta, 2932

N. diseases: 393; N. variants: 25
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.070 AlteredExpression disease BEFREE The inhibition of miR-214 reduces the proliferation of gastric cancer cells via upregulation of GSK-3β and suppression of Wnt/β-catenin signal pathway, which provides fundamental support for the future therapy of gastric cancer. 29364479 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.070 Biomarker disease BEFREE Downregulation of Annexin A11 (ANXA11) Inhibits Cell Proliferation, Invasion, and Migration via the AKT/GSK-3β Pathway in Gastric Cancer. 29306955 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.070 AlteredExpression disease BEFREE Taken together, we suggest that high glucose and elevated O-GlcNAcylation stabilize FOXM1 protein by its reduced degradation via GSK-3β inactivation in MKN45 cells, suggesting that the higher risk of gastric cancer in diabetic patients could be partially due to O-GlcNAcylation-mediated FOXM1 stabilization. 29196265 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.070 AlteredExpression disease BEFREE Silencing of CUL4B also resulted in decreased Wnt and β‑catenin expression, but increased expression of GSK‑3β, caspase‑3 and cyclin E. These results indirectly demonstrate that CUL4B enhances the proliferation and invasion abilities of gastric cancer cells by upregulating the constituent factors Wnt and β‑catenin, as well as by negatively regulating the mRNA and protein expression of GSK‑3β, caspase‑3 and cyclin E. The potential mechanism of CUL4B highlighted in the present study may be helpful for the treatment of patients with gastric cancer. 29393470 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.070 Biomarker disease BEFREE Our results indicated PTEN gene might induce cell invasion and migration via regulating AKT/GSK-3β/β-catenin signaling pathway, playing a vital role in the progression of gastric cancer. 29030742 2017
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.070 Biomarker disease BEFREE Thus, dual use of STAT3 and GSK-3β inhibitors may enhance the efficacy of the anti-metastatic treatment of gastric cancer. 25846563 2015
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.070 AlteredExpression disease BEFREE Taken together, the GSK3B, CTNNB1 and NOTCH2 expression signature is a novel, promising prognostic parameter for GC. 22970250 2012